Skip to main content

ATNM

Stock
Health Care
Biotechnology

Performance overview

ATNM Price
Price Chart

Forward-looking statistics

Beta
1.33
Risk
94.04%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Company info

SectorHealth Care
IndustryBiotechnology
Employees52
Market cap$237.1M

Fundamentals

Enterprise value-$20.2M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity5.58

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$1.47
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$715K
Avg trading volume (10 day)$1M
Put-call ratio

Macro factor sensitivity

Growth+8.7
Credit+32.3
Liquidity-16.1
Inflation+3.4
Commodities+2.4
Interest Rates+0.1

Valuation

Dividend yield0.00%
PEG Ratio-2.09
Price to sales
P/E Ratio-2.09
Enterprise Value to Revenue
Price to book1.75

Upcoming events

Next earnings dayMay 10, 2025
Next dividend day
Ex. dividend day

News

All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy

Actinium (ATNM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (October 18, 2024)
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment

On Monday, the FDA determined that Actinium Pharmaceuticals, Inc.'s ATNM Phase 3 SIERRA trial is not adequate to support a Biologics License Application (BLA) filing for Iomab-B despite its statistically significant primary endpoint.

Benzinga (August 5, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free